Skip to main content

Develop Novel Medicines for Once Monthly Intranasal Administration Designed to Mitigate Clinical Symptoms Associated With Respiratory Diseases

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Sep 11, 2015
Award amount: 
Organization name: 
Symmune Therapeutics, LLC
Principal Investigator: 
Lyman, Scott
Grant program category: 
Business Financing
Grant program name: 
Small Business Research Loan
Research Triangle

Symmune Therapeutics is developing medicines designed to mitigate clinical symptoms associated with respiratory diseases, including, respiratory tract infections, allergic rhinitis, and asthma. The target product profile is a dry powder medicine for once monthly intranasal administration.

Fiscal year: